このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

子宮内膜がんにおけるセンチネルリンパ節生検 (ENDO-3)

2026年11月11日 更新者:Queensland Centre for Gynaecological Cancer

明らかな初期段階の子宮内膜がんにおける後腹膜リンパ節郭清なしのセンチネルリンパ節生検を比較する第 III 相ランダム化臨床試験

Endometrial cancer (EC) is the most common gynaecological cancer. Current treatment of EC typically includes removal of the uterus and to determine the extent of the disease (removal of fallopian tubes, ovaries & if required a lymph node dissection (surgical staging)). While lymph node dissection may be valuable to guide the need for adjuvant treatment (chemo or radiotherapy) after surgery, it has been a topic of controversy for the last 30 years. In some patients it causes morbidity, specifically lymphoedema. This recently has been replaced with sentinel node biopsy (SNB). It requires an injection of a dye into the cervix with specific equipment & surgical dissection of the lymph node in which the dye first becomes visible. Despite this promising proposition & similar to a lymph node dissection, the value to patients, cost effectiveness & potential harms (e.g. lymphedema) of SNB compared to no-node dissection in EC has never been established. Aim: determine the value of SNB for patients, the healthcare system and exclude detriment to patients using a randomised approach 1:1. Stage 1 - 444 patients. Stage 2 additional 316 patients.

Primary Outcome Stage 1:

Proportion of participants returning to usual daily activities at 12 months from surgery using the EQ-5D which will determine when women in both groups can return to their usual activities.

Primary Outcome Stage 2:

Treatment non-inferiority as evaluated by disease-free survival status at 4.5 years post-surgery, as measured by the time interval between the date of randomisation and date of first recurrence. Confirmation of recurrent disease will be ascertained through clinical assessment, radiological work-up and/or histological results.

調査の概要

状態

募集

条件

介入・治療

詳細な説明

Hypothesis: The primary hypothesis is that SNB will not cause detriment to patients (lymphoedema, morbidity, loss of quality of life) and not increase costs compared to patients without a retroperitoneal node dissection. The secondary hypothesis is that disease-free survival in patients without retroperitoneal node dissection is not inferior to those receiving SNB.

Aims: To determine the value of SNB for patients, the healthcare system and to exclude detriment to patients.

Objectives:

Primary Stage 1:

To determine the recovery of participants (defined as incidence of adverse events, lower limb lymphoedema and health-related QOL) and to the healthcare system (cost) of Sentinel Node Biopsy (SNB) for the surgical treatment of endometrial cancer.

Primary Stage 2:

Compare disease-free survival at 4.5 years for participants randomised to receive hysterectomy, bilateral salpingo-oophorectomy with SNB compared to participants randomised to hysterectomy, bilateral salpingo-oophorectomy without retroperitoneal node dissection.

Secondary:

  • Compare patterns of recurrence and overall survival (OS) between the groups
  • Determine the cost-effectiveness of SNB
  • Compare Patient Reported Outcomes (PROMS) between the groups at 12 months from surgery
  • Compare Health Related Quality of Life (HRQL) and Fear of Recurrence between the groups at 12 months from surgery
  • Compare perioperative outcomes (duration of surgery, length of hospital stay, intraoperative blood loss, blood transfusion requirements) and the incidence of intra- and postoperative adverse events within 12 months from surgery between the groups
  • Compare lower limb lymphoedema at 12 months after surgery
  • Compare the need for postoperative (adjuvant) treatments between groups
  • Determine the impact of body composition and frailty on survival, quality of life, lymphoedema, peri-, intra- and postoperative outcomes
  • Compare follow-up strategies (clinical vs symptom checklist)
  • Translational Research - Trans-ENDO 3 - biobanking strategy - Compare the Molecular profile at 12 months from surgery between the groups

研究の種類

介入

入学 (推定)

760

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

    • Texas
      • Houston、Texas、アメリカ、77030
        • 募集
        • Houston Methodist Hospital
        • コンタクト:
        • コンタクト:
        • 主任研究者:
          • Behrouz Zand, MD
        • 副調査官:
          • Tarrik Zaid, MD
        • 副調査官:
          • Aparna Kamat, MD
        • 副調査官:
          • Anju Suri, MD
        • 副調査官:
          • Pedro Ramirez, MD
    • Ciudad Autónoma de Buenos Aires (caba)
      • Buenos Aires、Ciudad Autónoma de Buenos Aires (caba)、アルゼンチン
      • Buenos Aires、Ciudad Autónoma de Buenos Aires (caba)、アルゼンチン
        • 募集
        • Hospital Britanico
        • コンタクト:
        • 主任研究者:
          • Julian Di Guilmi, MD
    • Via Pozzuolo
    • New South Wales
      • Camperdown、New South Wales、オーストラリア、2050
      • Liverpool、New South Wales、オーストラリア、2170
    • Queensland
      • Auchenflower、Queensland、オーストラリア、4066
        • 募集
        • The Wesley Hospital
        • コンタクト:
        • 主任研究者:
          • Andrea Garrett, MD
        • 副調査官:
          • Rhett Morton, MD
        • コンタクト:
      • Brisbane、Queensland、オーストラリア、4120
        • 募集
        • Greenslopes Private Hospital
        • コンタクト:
        • コンタクト:
        • 主任研究者:
          • Shaun McGrath, MD
      • Buderim、Queensland、オーストラリア、4556
        • 募集
        • Buderim Private Hospital
        • コンタクト:
        • 主任研究者:
          • Andreas Obermair, MD
        • コンタクト:
      • Everton Park、Queensland、オーストラリア、4053
        • 募集
        • North West Private Hospital
        • コンタクト:
        • 主任研究者:
          • Piksi Singh, MD
        • コンタクト:
      • Herston、Queensland、オーストラリア、4029
        • 募集
        • Royal Brisbane and Women's Hospital
        • コンタクト:
        • 主任研究者:
          • Andrea Garrett, MD
        • 副調査官:
          • Andreas Obermair, MD
        • 副調査官:
          • Russell Land, MD
        • 副調査官:
          • Piksi Singh, MD
        • 副調査官:
          • Shaun McGrath, MD
        • コンタクト:
      • South Brisbane、Queensland、オーストラリア、4101
        • 募集
        • Mater Hospital
        • コンタクト:
        • 副調査官:
          • Nisha Jagasia, MD
        • 副調査官:
          • Nimithri Cabraal, MD
        • 副調査官:
          • Rhett Morton, MD
        • 主任研究者:
          • Naven Chetty, MD
        • コンタクト:
        • 副調査官:
          • Simon West, MD
      • Southport、Queensland、オーストラリア、4215
        • まだ募集していません
        • Gold Coast University Hospital
        • コンタクト:
        • 主任研究者:
          • Elizabeth Goulding, MD
        • コンタクト:
      • Spring Hill、Queensland、オーストラリア、4000
        • 募集
        • St Andrews War Memorial Hospital
        • コンタクト:
        • 主任研究者:
          • Andreas Obermair, MD
        • コンタクト:
    • Victoria
      • Heidelberg、Victoria、オーストラリア、3084
      • Melbourne、Victoria、オーストラリア、3002
        • 募集
        • Epworth Freemasons
        • コンタクト:
        • 主任研究者:
          • Adam Pendlebury, MD
      • Parkville、Victoria、オーストラリア、3052
    • Antioquia
      • Medellín、Antioquia、コロンビア、050025
        • 募集
        • Promotora Médica Las Américas S.A.
        • コンタクト:
        • 主任研究者:
          • Gabriel Rendon, MD
    • Bogotá, Distrito Capital
      • Bogotá、Bogotá, Distrito Capital、コロンビア、110131
        • 募集
        • Centro de tratamiento e investigación sobre Cáncer Luis Carlos Sarmiento Angulo
        • コンタクト:
        • コンタクト:
        • 主任研究者:
          • David Viveros, MD
    • NUH Zone B
      • Singapore、NUH Zone B、シンガポール、119074
        • 募集
        • National University Hospital and National University Cancer Institute
        • コンタクト:
        • コンタクト:
        • 主任研究者:
          • Joseph Ng Soon Yau, MD
        • 副調査官:
          • Pearl S Tong, MD
        • 副調査官:
          • Jeffrey Low, MD
        • 副調査官:
          • Jeslyn Wong, MD
    • São Paulo
      • São José do Rio Preto、São Paulo、ブラジル、15090-000
        • 募集
        • Hospital de Base
        • コンタクト:
        • 主任研究者:
          • Guilherme Accorsi, MD
      • São Paulo、São Paulo、ブラジル
      • São Paulo、São Paulo、ブラジル
        • 募集
        • Hospital Israelita Albert Einstein
        • コンタクト:
        • コンタクト:
          • Renato
        • 主任研究者:
          • Renato Moretti-Marques, MD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

女性

説明

Inclusion Criteria:

  1. Females, over 18 years, with histologically confirmed primary epithelial cancer of the endometrium of any cell type or uterine carcinosarcoma (mixed malignant mullerian tumour);
  2. Clinically stage I disease (disease confined to body of uterus);
  3. Eastern Cooperative Oncology Group (ECOG) performance status of ≤2;
  4. Signed written informed consent;
  5. Participant must meet criteria for a laparoscopic or robotic surgical approach as determined by the treating physician (e.g. suitable for TH BSO, ability to tolerate Trendelenberg positioning)
  6. All available clinical evidence (physical examination findings, or medical imaging such as CT, MRI or ultrasound) demonstrates no evidence of extrauterine disease
  7. Myometrial Invasion on MRI of not more than 50%. (Only if participant is <45yo, has ONLY Grade 1 EAC and wishes to retain their ovaries).
  8. Negative (serum or urine) pregnancy test ≤ 30 days of surgery in pre-menopausal women and women < 2 years after the onset of menopause.

Exclusion Criteria:

  1. Evidence of extrauterine disease (apparent involvement of cervix, vagina, parametria, adnexa, lymph nodes, bladder, bowel or distant sites) by clinical examination and/or through medical imaging.
  2. Enlarged retroperitoneal pelvic and/or aortic lymph nodes (>1 cm) on medical imaging;
  3. Estimated life expectancy of less than 6 months;
  4. Patients who have absolute contraindications for adjuvant radiotherapy and/or chemotherapy;
  5. Patients who have previously received radiation treatment to the pelvis
  6. Serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator);
  7. Patient compliance and geographic proximity that do not allow adequate follow-up;
  8. Patients with allergy to Indocyanine Green (ICG)
  9. Patients who have had previous retroperitoneal surgery
  10. Patients who require a retroperitoneal (pelvic +/- para-aortic) lymph node dissection (lymphadenectomy)
  11. Other prior malignancies <5 years before inclusion, except for successfully treated keratinocyte skin cancers, or ductal carcinoma of the breast insitu
  12. Uterine perforation during endometrial tissue sampling

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:TH BSO with SNB

Total Laparoscopic/Robotic Hysterectomy, Bilateral Salpingo-Oophorectomy (TH BSO) with Sentinel Node Biopsy (SNB) using Indocyanine Green (ICG)+/- Methylene Blue Dye (+/- omentectomy in high risk cell types) Note: If participants (≤45 years of age), have Grade 1 endometrial adenocarcinoma (EAC) with myometrial invasion <50% (by MRI) and wish to retain their ovaries a BSO may be omitted.

Removal of uterus, tubes and ovaries with a sentinel node biopsy. A tracer dye (ICG) +/- Methylene Blue Dye is injected into the surroundings of the primary tumour, it is transported via local lymphatic channels towards the draining lymphatic basin, and the first node that the tracer reaches is called the "sentinel node". These one or two nodes are thought to be first involved with cancer spread.

アクティブコンパレータ:TH BSO without retroperitoneal node dissection

Total Laparoscopic/Robotic Hysterectomy, Bilateral Salpingo-Oophorectomy (TH BSO) without retroperitoneal node dissection (+/- omentectomy in high risk cell types) Note: If participants (≤45 years of age), have Grade 1 endometrial adenocarcinoma (EAC) with myometrial invasion <50% (by MRI) and wish to retain their ovaries a BSO may be omitted.

Removal of uterus, tubes and ovaries without retroperitoneal node dissection

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Stage 1: Return to usual activities
時間枠:12 months from surgery

Proportion of participants returning to usual daily activities at 12 months from surgery using the EQ-5D which will determine when women in both groups can return to their usual activities.

12 months from surgery
Stage 2: Disease Free Survival
時間枠:4.5 years from surgery

Compare disease-free survival for participants randomised to receive hysterectomy, bilateral salpingo-oophorectomy with SNB compared to participants randomised to hysterectomy, bilateral salpingo-oophorectomy without retroperitoneal node dissection

4.5 years from surgery

二次結果の測定

結果測定
メジャーの説明
時間枠
Cost Effectiveness using QALYs using EuroQoL-5D (EQ-5D) Questionnaire
時間枠:12 months from surgery

An assessment will be performed on the cost-effectiveness of TH + SNB relative to TH alone, calculated as the incremental cost per unit of improvement in functional outcome, measured in terms of the primary outcome. This will assess how much more money the proposed intervention will cost the health system and society, and whether this represents a sound investment in terms of the improvement in quality of life. We will also measure the quality-adjusted life years (QALYs) gained with the intervention and use this to undertake a cost-utility analysis. The QALY calculations will be based on health status measures for trial participants, with valuations of changes in health status and quality of life based on the EQ-5D

12 months from surgery
Cost Effectiveness measuring Intervention costs
時間枠:12 months from surgery

An assessment will be performed on the cost-effectiveness of TH + SNB relative to TH alone, calculated as the incremental cost per unit of improvement in functional outcome, measured in terms of the primary outcome. This will assess how much more money the proposed intervention will cost the health system and society.

12 months from surgery
Cost Effectiveness measuring GP and specialist consultations
時間枠:12 months from surgery

An assessment will be performed on the cost-effectiveness of TH + SNB relative to TH alone, calculated as the incremental cost per unit of improvement in functional outcome, measured in terms of the primary outcome. This will assess how much more money the proposed intervention will cost the health system and society, and whether this represents a sound investment in terms of the improvement in quality of life.

12 months from surgery
Cost Effectiveness measuring radiology and imaging requirements
時間枠:12 months from surgery

An assessment will be performed on the cost-effectiveness of TH + SNB relative to TH alone, calculated as the incremental cost per unit of improvement in functional outcome, measured in terms of the primary outcome. This will assess how much more money the proposed intervention will cost the health system and society.

12 months from surgery
Cost Effectiveness measuring prescriptions and over the counter medicine requirements
時間枠:12 months from surgery

An assessment will be performed on the cost-effectiveness of TH + SNB relative to TH alone, calculated as the incremental cost per unit of improvement in functional outcome, measured in terms of the primary outcome. This will assess how much more money the proposed intervention will cost the health system and society, and whether this represents a sound investment in terms of the improvement in quality of life.

12 months from surgery
Cost Effectiveness measuring community and health service requirements and days off work and informal care required by family and friends using a combination of the Health Services Questionnaire and clinical files
時間枠:12 months from surgery

An assessment will be performed on the cost-effectiveness of TH + SNB relative to TH alone, calculated as the incremental cost per unit of improvement in functional outcome, measured in terms of the primary outcome. This will assess how much more money the proposed intervention will cost the health system and society, and whether this represents a sound investment in terms of the improvement in quality of life.

12 months from surgery
Cost Effectiveness: direct costs using a bottom-up approach by recording the volume of resource use in both groups of the trial, and then applying a unit cost to each component
時間枠:12 months from surgery

Direct costs wukk be ibtained for smaples of participants, stratified by hospital, operation and outcome to assess the cost-effectiveness of TH + SNB relative to TH alone, calculated as the incremental cost per unit of improvement in functional outcome, measured in terms of the primary outcome. This will assess how much more money the proposed intervention will cost the health system and society.

12 months from surgery
Perioperative Outcomes: Adverse Events
時間枠:12 months from surgery

Compare perioperative outcomes and the incidence of intra- and postoperative adverse events within 12 months from surgery between groups using Common Terminology Criteria for Adverse Events (CTCAE version 5)

12 months from surgery
Perioperative Outcomes: Length of Surgery
時間枠:At time of surgery

Compare the length of surgery between the two groups. This will be recorded in hh:mm on the surgery form.

At time of surgery
Perioperative Outcomes: Blood Loss during Surgery
時間枠:At time of surgery

Compare the blood loss between the two groups during surgery. This will be recorded in ml.

At time of surgery
Perioperative Outcomes: Blood Transfusion Requirements during Surgery
時間枠:At time of surgery

Compare the blood transfusion requirements between the two groups. This will be recorded in units and recorded on the Surgery Form and the Concomitant Medication Form.

At time of surgery
Perioperative Outcomes: Length of Hospital Stay
時間枠:At time of discharge from hospital following surgery

Compare the length of hospital stay between the two groups. The duration will be measured in days. Date of surgery being day 0.

At time of discharge from hospital following surgery
Health Related Quality of Life and Fear of Recurrence
時間枠:12 months from surgery

Change in Quality of Life using Functional Assessment of Cancer General (FACT-EN), Fear of Recurrence and PROMS between baseline and 1 year after surgery

12 months from surgery
Incidence of Lymphedema
時間枠:12 months from surgery

Compare lower limb lymphedema between groups

12 months from surgery
Adjuvant Treatment Requirements
時間枠:12 months from surgery

Compare the need for postoperative (adjuvant) treatments between groups and evaluate the impact of SNB on clinical decisions regarding adjuvant treatment. Any chemotherapy or radiation therapy required will be recorded on specific chemotherapy or radiation forms. Chemotherapy will be recorded in mg received and number of doses required including start/end dates. Radiation treatment received will be recorded as total dose of Gy and how many fractions, including start and end dates.

12 months from surgery
Value of Molecular Biomarkers
時間枠:24 months from surgery

Translational Research - Compare Molecular profile from surgery between the groups that require adjuvant therapy for 24 months.

24 months from surgery
Value of Molecular Biomarkers
時間枠:12 months from surgery

Translational Research - Compare the Molecular profile of Germline DNA at 12 months from surgery between the groups

12 months from surgery
Value of Molecular Biomarkers
時間枠:12 months from surgery

Translational Research - Compare the Molecular profile of Circulating Tumour DNA at 12 months from surgery between the groups

12 months from surgery
Value of Molecular Biomarkers
時間枠:12 months from surgery

Translational Research - Compare the Molecular profile of Plasma at 12 months from surgery between the groups

12 months from surgery
Value of Molecular Biomarkers
時間枠:12 months from surgery

Translational Research - Compare the Molecular profile of Serum at 12 months from surgery between the groups

12 months from surgery
Overall Survival
時間枠:4.5 years from surgery

Compare overall survival for participants randomised to receive hysterectomy, bilateral salpingo-oophorectomy with SNB compared to participants randomised to hysterectomy, bilateral salpingo-oophorectomy without retroperitoneal node dissection

4.5 years from surgery
Patterns of Recurrence - date and localization of 1st recurrence
時間枠:4.5 years from surgery

Date and localization of 1st recurrence as confirmed histologically and/or radiologically - Compare these patterns of recurrences between the groups. These will also be adjudicated by an independent committee to ensure accuracy of documented recurrence

4.5 years from surgery
Impact of body composition (sarcopenia) on surgical complications, recovery and overall survival
時間枠:4.5 years from surgery

Body mass measures are practical & sensitive for predicting health risks & outcomes. Sarcopenia is defined as loss of skeletal muscle mass & strength. It's been found to be associated with procedure-related morbidity, survival in cancer patients and increased use of healthcare. The concurrent appearance of low muscle mass with high adiposity (sarcopenic obesity) is common in people with chronic diseases. The trial will determine the role sarcopenia has on participants pre-operatively (via CT images & Bioimpedance Spectroscopy (BIS - if available at site) & postoperatively using the BIS in regard to survival in gynaecological malignancies, if it is a predictive factor for treatment adverse events & participants tolerability of treatment & compare diagnostic methods to determine medical fitness for surgery. BIS sends non-detectable electrical currents, at a range of frequencies through the body allowing precise measurement & analysis of impedance to currents by extracellular fluid

4.5 years from surgery
Impact of frailty on surgical complications, recovery and overall survival
時間枠:4.5 years from surgery

It has been reported consistently that frailty has a significant impact on the occurrence of adverse postoperative outcomes. Therefore, measuring frailty is important to estimate risks, determine the best treatment options, and to aid diagnosis and care planning. Frailty will be measured prior to surgery suing the validated tool - Frailty Phenotype. This may determine the impact frailty has on survival, quality of life, lymphedema, peri-, intra- and postoperative outcomes

4.5 years from surgery
Follow-Up Strategies
時間枠:4.5 years from surgery

Current institutional & clinical guidelines suggest patients need to be seen at regular follow up visits. The risk of developing a recurrence is higher within the initial period after surgery & the majority of recurrences develop within those first 3 years. Participants will ideally be seen 3 monthly for the first 3 years & 6 monthly until 4.5 years. The objective of follow up is that local recurrences from endometrial cancer are potentially curable. It helps to diagnose local recurrences as early as possible so that they are amenable for curative or effective palliative management. We will compare these clinical findings to a symptom checklist that will be completed by participants every 3 months from surgery until 4.5 years. This records patient reported symptoms that may indicate a recurrence. Comparing these findings should determine effective follow up strategies for this group of patients.

4.5 years from surgery

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

捜査官

  • スタディチェア:Andreas Obermair, Prof、Director, Queensland Centre for Gynaecological Cancer Research

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年1月18日

一次修了 (推定)

2031年1月1日

研究の完了 (推定)

2031年2月1日

試験登録日

最初に提出

2019年8月26日

QC基準を満たした最初の提出物

2019年8月27日

最初の投稿 (実際)

2019年8月29日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月16日

QC基準を満たした最後の更新が送信されました

2026年11月11日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • ENDO-3

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。